P-266: Favorable outcomes of 3-weekly daratumumab-based regimens in relapsed/refractory multiple myeloma: impact of MRD, rapid doubling time, LDH, triplets and quadruplets
- Resource Type
- Abstract
- Source
- In
Clinical Lymphoma, Myeloma and Leukemia August 2022 22 Supplement:S184-S184 - Subject
- Language
- ISSN
- 2152-2650